Is Compounded Tirzepatide the Same as Mounjaro or Zepbound?
Same active molecule, different products, different FDA standing. Here is the clear, current, physician-reviewed answer — and what actually matters for your safety.
Medically reviewed by Charles Kamen, MD, board-certified neurologist ·
Compounded tirzepatide contains the same active molecule as Mounjaro and Zepbound — tirzepatide, a dual GIP/GLP-1 receptor agonist — but it is not the same product. Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management and obstructive sleep apnea) are specific FDA-approved finished drugs, manufactured by Eli Lilly with fixed formulations, standardized labeling, and ongoing FDA quality oversight. Compounded tirzepatide is prepared by a licensed compounding pharmacy and is not itself an FDA-approved finished drug.
That difference is the whole answer to the question, and it has three practical parts: what “FDA-approved” actually covers, the distinction between Mounjaro and Zepbound, and when compounding tirzepatide is legally permitted. We are a physician practice, not a medication retailer, so the goal here is to explain the distinction clearly — the decision itself belongs in a medical evaluation.
What does “FDA-approved” cover here?
FDA approval applies to specific finished products, not to a molecule in general. Eli Lilly’s tirzepatide products — Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea — are FDA-approved finished drugs. Compounded tirzepatide uses the same active molecule but is a pharmacy preparation, not an approved product, so it does not carry the same standing even though the molecule is identical. See our GLP-1 medication comparison for a full side-by-side of approved and investigational incretin agents, and our which peptides are FDA-approved reference for the broader principle: the useful question is always which exact product, not just the ingredient name.
Mounjaro vs Zepbound: same molecule, different FDA indications
Mounjaro and Zepbound are both Eli Lilly brand-name tirzepatide, but they are FDA-approved for different uses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults and, as of 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity — making tirzepatide the first medication ever FDA-approved for OSA. The molecule tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors; this dual mechanism distinguishes it from semaglutide, which is a single GLP-1 receptor agonist. For a full comparison of these two agents and others, see our semaglutide vs tirzepatide vs retatrutide physician-reviewed comparison.
When is compounding tirzepatide permitted?
Compounding a drug that copies an FDA-approved product is generally restricted under federal law, with an important exception during periods when the FDA lists the drug as in shortage. Because shortage status and the resulting compounding eligibility shift over time, this is exactly the kind of fact to verify at the time of care rather than assume from any web page. Our FDA compounding status tracker and our 503A vs 503B compounding pharmacy guide explain why these distinctions matter and how licensed pharmacies differ.
How do you source compounded tirzepatide safely?
Safety comes down to sourcing. Legitimate compounded tirzepatide is dispensed by a licensed 503A or 503B pharmacy after a physician evaluation, with third-party purity and potency testing. The danger is the unregulated market — “research use only” vials and unverified powders that are not made or tested for human use.
Mounjaro (type 2 diabetes) and Zepbound (weight management; sleep apnea) are FDA-approved finished drugs — same molecule, distinct products with different indications
No compounded drug is FDA-approved, including compounded tirzepatide
Compounding eligibility tracks FDA shortage status, which changes over time
Legitimate compounded tirzepatide comes from a licensed 503A/503B pharmacy with a valid prescription after physician evaluation
Avoid "research use only" vials or unverified powders — not made or tested for human use
Whether a GLP-1/GIP medication is right for you is a physician decision, never a checkout decision
Compounded Tirzepatide vs Mounjaro/Zepbound — FAQ
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No — compounded tirzepatide and Mounjaro/Zepbound share the same active molecule (tirzepatide, a dual GIP/GLP-1 receptor agonist) but are not the same product. Mounjaro and Zepbound are specific FDA-approved finished drugs manufactured by Eli Lilly with fixed formulations, standardized labeling, and ongoing FDA quality oversight. Compounded tirzepatide is prepared by a licensed compounding pharmacy and is not an FDA-approved finished drug. Same molecule, different product, different regulatory standing.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound are both brand-name tirzepatide made by Eli Lilly, but they are FDA-approved for different indications: Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management and, as of 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever FDA-approved for OSA. The active molecule, tirzepatide, is identical in both; the products differ by FDA-approved indication and labeling.
Is compounded tirzepatide FDA-approved?
No — no compounded drug is FDA-approved, including compounded tirzepatide. The FDA approves specific finished products such as Mounjaro and Zepbound — not compounded preparations. Compounded tirzepatide is made by a licensed 503A or 503B pharmacy under state and federal compounding rules; the individual preparation has not gone through the FDA new-drug approval process even though the active molecule is the same.
When is compounding tirzepatide legally permitted?
Compounding a drug that copies an FDA-approved product is generally restricted under federal law, with an important exception during periods when the FDA lists the drug as in shortage. Because shortage status and the resulting compounding eligibility shift over time, this is exactly the kind of fact to verify at the time of care rather than assume from any web page. Our FDA compounding status page explains why these distinctions matter and change.
Is compounded tirzepatide safe?
Safety depends almost entirely on sourcing. Compounded tirzepatide from a licensed 503A or 503B pharmacy, dispensed after a physician evaluation with third-party purity and potency testing, is a regulated medical preparation. Products sold online as "research use only" tirzepatide, or unverified powders, are not made or tested for human use and carry real risk. The FDA has issued warnings about adverse events linked to compounded and counterfeit GLP-1/GIP products from unregulated sources. Individual risks and appropriateness must be assessed by a licensed physician.
Should I choose compounded tirzepatide or brand-name Mounjaro/Zepbound?
That is a medical decision, not a shopping decision, and it depends on your health profile, insurance coverage, availability, and clinical goals. A legitimate physician evaluates whether a GLP-1/GIP medication is appropriate for you at all, then discusses FDA-approved options and, where compounding is legally permitted and clinically appropriate, licensed-pharmacy compounded options — with honest information about the regulatory and safety differences. No web page can make that call for you.
How do I avoid fake or unsafe compounded tirzepatide?
Use a physician-led clinic that dispenses only through a named, licensed 503A or 503B compounding pharmacy, requires a valid prescription after medical evaluation, and can provide certificates of analysis showing third-party testing. Avoid any vendor selling tirzepatide directly without a prescription, labeling it "research use only," or omitting pharmacy licensing information — these are hallmarks of gray-market and counterfeit products.
Related reading: 503A vs 503B compounding pharmacies · Tirzepatide in Las Vegas · GLP-1 medications compared · Is compounded semaglutide the same as Ozempic? · FDA compounding status
Physician-Led in Las Vegas
Questions about tirzepatide? Ask a physician.
Whether a GLP-1/GIP medication fits your health is a clinical decision. Start with an $88 medical evaluation, and Dr. Kamen will review your options honestly — FDA-approved Mounjaro or Zepbound and, where appropriate, licensed-pharmacy compounded options — with transparent sourcing. See our Las Vegas peptide clinic for what to expect.
Ready to Start Your Longevity Journey?
Book your $88 evaluation with Dr. Kamen today — online, by phone, or by text.
Book Your $88 EvaluationPrefer to talk? Call (702) 808-2650 or text us to book.
physician-led peptide therapy Las Vegas — visit our clinic